专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110081427A1 Nitroxyl Progenitors in the Treatment of Heart Failure 审中-公开
标题翻译：硝酸基因祖细胞治疗心力衰竭
公开(公告)号：US20110081427A1
公开(公告)日：2011-04-07
申请号：US12949533
申请日：2010-11-18
申请人： David A. Wink , Martin Feelisch , David A. Kass , Nazareno Paolocci , Katrina Miranda , Jon Fukuto , Tatsuo Katori
发明人： David A. Wink , Martin Feelisch , David A. Kass , Nazareno Paolocci , Katrina Miranda , Jon Fukuto , Tatsuo Katori
IPC分类号： A61K33/00 , A61P9/04 , A61K31/655
CPC分类号： A61K31/655 , A61K31/13 , A61K31/16 , A61K33/00 , A61K2300/00
摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
摘要翻译：施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。另外，与使用NO-供体观察到的效果相反，将HNO / NO供体与正性肌力药物联合给药不会损害正性肌力药物的正性肌力作用。此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

2. 发明申请

US20090028798A1 METHOD FOR DETERMINING REDOX STATUS OF A TISSUE 审中-公开
标题翻译：用于确定组织的氧化还原状态的方法
公开(公告)号：US20090028798A1
公开(公告)日：2009-01-29
申请号：US11997236
申请日：2006-08-10
申请人： James B. Mitchell , Murali K. Cherukuri , John A. Cook , Fuminori Hyodo , Alan P. Koretsky , Ken-Ichiro Matsumoto , Sankaran Subramanian , David A. Wink
发明人： James B. Mitchell , Murali K. Cherukuri , John A. Cook , Fuminori Hyodo , Alan P. Koretsky , Ken-Ichiro Matsumoto , Sankaran Subramanian , David A. Wink
IPC分类号： A61K49/08
CPC分类号： A61B5/055 , A61K49/10 , A61K49/20
摘要： Disclosed is a method for determining the redox status of a region of interest in an animal tissue. The method includes administering a nitroxyl contrast agent to the region of interest, obtaining a magnetic resonance image of the region of interest, determining the amount of reduced nitroxyl contrast agent in the region of interest, and thereby determining the redox status of the region of interest.
摘要翻译：公开了一种用于确定动物组织中感兴趣区域的氧化还原状态的方法。该方法包括向感兴趣区域施用硝酰基造影剂，获得感兴趣区域的磁共振图像，确定感兴趣区域中还原的硝酰基造影剂的量，从而确定感兴趣区域的氧化还原状态。

3. 发明授权

US5603820A Nitric oxide sensor 失效
标题翻译：一氧化氮传感器
公开(公告)号：US5603820A
公开(公告)日：1997-02-18
申请号：US477620
申请日：1995-06-07
申请人： Tadeusz Malinski , David A. Wink , Janet Younathan , Royce W. Murray , Melani Sullivan , Thomas J. Meyer , Danae D. Christodoulou
发明人： Tadeusz Malinski , David A. Wink , Janet Younathan , Royce W. Murray , Melani Sullivan , Thomas J. Meyer , Danae D. Christodoulou
IPC分类号： B01J31/16 , B01J31/18 , G01N27/30 , G01N27/416 , G01N33/00 , G01N27/26
CPC分类号： B01J31/1815 , B01J31/1658 , G01N27/4045 , B01J2531/025 , B01J2531/842 , B01J2531/845 , B01J2531/847
摘要： An electrode sensor which may be used to specifically and quantitatively measure nitric oxide is provided, as well as a method of preparing and using such an electrode sensor to measure nitric oxide concentration in solution. A nitric oxide (NO) microsensor based on catalytic oxidation of NO comprises a thermally-sharpened carbon fiber with a tip diameter of about 0.5-0.7 .mu.m coated with several layers of p-type semiconducting polymeric porphyrin and cationic exchanger deposited thereon. The microsensor, which can be operated in either the amperometric, voltammetric or coulometric mode utilizing a two or three electrode system, is characterized by a linear response up to about 300 .mu.M, a response time better than 10 msec and a detection limit of about 10 nM. The sensor of the present invention also discriminates against nitrite, the most problematic interferant in NO measurements. The amount of NO released from a single cell can thus be selectively measured in situ by a porphyrinic microsensor of the invention. A larger scale sensor utilizing porphyrin and cationic exchanger deposited on larger fibers or wires, platinum mesh or tin indium oxide layered on glass, can also be employed when measurement of NO concentration in chemical media, tissue or cell culture is desired.
摘要翻译：提供了可用于特异性和定量测量一氧化氮的电极传感器，以及制备和使用这种电极传感器来测量溶液中的一氧化氮浓度的方法。基于NO的催化氧化的一氧化氮（NO）微量传感器包括具有约0.5-0.7μm的尖锐直径的碳纤维，其涂覆有几层p型半导体聚合物卟啉和沉积在其上的阳离子交换剂。可以使用两个或三个电极系统以电流，伏安或库仑模式操作的微传感器的特征在于线性响应高达约300μM，响应时间优于10msec，检测限为约 10nM。本发明的传感器还可以区分NO测量中最有问题的干扰物亚硝酸盐。因此，可以通过本发明的卟啉微传感器原位选择性地测量从单个电池释放的NO的量。当需要在化学介质，组织或细胞培养物中测量NO浓度时，也可以使用沉积在较大纤维或电线上的卟啉和阳离子交换剂的更大规模的传感器，铂玻璃或层状玻璃上的氧化铟锡。

4. 发明授权

US5208233A Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof 失效
标题翻译：仲胺 - 一氧化氮加合物的抗高血压组合物及其用途
公开(公告)号：US5208233A
公开(公告)日：1993-05-04
申请号：US743892
申请日：1991-08-12
申请人： Larry K. Keefer , David A. Wink , Tambra M. Dunams , Joseph A. Hrabie
发明人： Larry K. Keefer , David A. Wink , Tambra M. Dunams , Joseph A. Hrabie
IPC分类号： A61K31/13 , A61K31/135 , A61K31/395 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/535 , C07C291/08 , C07C307/02 , C07D295/28
CPC分类号： C07D295/30 , A61K31/13 , A61K31/135 , A61K31/395 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/535 , C07C291/08 , C07C307/02
摘要： There are disclosed anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component in the anti-hypertensive compositions is a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl group; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a heterocyclic ring; M.sup.+X is a pharmaceutically acceptable cation, wherein x is the valence of the cation.
摘要翻译：公开了抗高血压组合物和降低哺乳动物血压的方法。抗高血压组合物中的活性组分是下式化合物：其中R 1和R 2独立地选自直链和支链C 1 -C 12烷基和苄基，条件是在α碳上不发生分支烷基的原子; 或R 1和R 2与它们所键合的氮原子一起形成杂环; M + X是药学上可接受的阳离子，其中x是阳离子的化合价。

5. 发明授权

US09012647B2 Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders 有权
标题翻译：硝基氧化物修饰的非甾体抗炎化合物及其在治疗和预防疾病或病症中的用途
公开(公告)号：US09012647B2
公开(公告)日：2015-04-21
申请号：US13440092
申请日：2012-04-05
申请人： David A. Wink , Wilmarie Flores-Santana , S. Bruce King , Murali Krishna Cherukuri , James B. Mitchell
发明人： David A. Wink , Wilmarie Flores-Santana , S. Bruce King , Murali Krishna Cherukuri , James B. Mitchell
IPC分类号： A61K31/445 , C07D211/00 , C07D401/12 , C07D211/94 , A61K47/48
CPC分类号： C07D401/12 , A61K47/48061 , A61K47/545 , C07D211/94
摘要： Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.
摘要翻译：公开了式（I）的硝基氧改性的NSAID化合物或其药学上可接受的盐或对映异构体：其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，R 10，R 11和n如本文所定义及其药物组合物。进一步公开的是在患者中治疗或预防各种疾病，例如炎症，癌症，糖尿病，心血管疾病，体重增加，息肉和/或慢性疼痛的方法，包括给予有效量的化合物或药学上可接受的盐或式（I）的对映异构体。还提供了在动物体内成像式（I）的化合物或药学上可接受的盐或对映异构体的方法。

6. 发明授权

US07863262B2 Nitroxyl progenitors in the treatment of heart failure 有权
标题翻译：硝基脯氨酸治疗心力衰竭
公开(公告)号：US07863262B2
公开(公告)日：2011-01-04
申请号：US11096924
申请日：2005-03-31
申请人： David A. Wink , Martin Feelisch , David A. Kass , Nazareno Paolocci , Katrina Miranda , Jon Fukuto , Tatsuo Katori
发明人： David A. Wink , Martin Feelisch , David A. Kass , Nazareno Paolocci , Katrina Miranda , Jon Fukuto , Tatsuo Katori
IPC分类号： A01N51/00 , A61K31/655 , A61K31/13 , A61K33/26
CPC分类号： A61K31/655 , A61K31/13 , A61K31/16 , A61K33/00 , A61K2300/00
摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
摘要翻译：施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。另外，与使用NO-供体观察到的效果相反，将HNO / NO供体与正性肌力药物联合给药不会损害正性肌力药物的正性肌力作用。此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

7. 发明授权

US06936639B2 Nitroxyl progenitors in the treatment of heart failure 有权
标题翻译：硝基脯氨酸治疗心力衰竭
公开(公告)号：US06936639B2
公开(公告)日：2005-08-30
申请号：US10226412
申请日：2002-08-21
申请人： David A. Wink , Martin Feelisch , David A. Kass , Nazareno Paolocci , Katrina Miranda , Jon Fukuto , Tatsuo Katori
发明人： David A. Wink , Martin Feelisch , David A. Kass , Nazareno Paolocci , Katrina Miranda , Jon Fukuto , Tatsuo Katori
IPC分类号： A61K31/13 , A61K31/16 , A61K31/19
CPC分类号： A61K31/655 , A61K31/13 , A61K31/16 , A61K33/00 , A61K2300/00
摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy
摘要翻译：施用HNO / NO - 辅助化合物如Angeli盐可增加心肌收缩力，同时降低经历心力衰竭的受试者的左心室预负荷。此外，给予HNO / 供体化合物异丙胺（IPA）/ NO（Na（CH 3 3）2 CHNHN（O）NO）令人惊讶地在经历心力衰竭的受试者中表现出正性肌力作用由HNO / NO - 捐赠化合物Angeli的盐引起的那些。另外，与使用NO-SUP供体观察到的效果相反，将HNO / NO + - 供体与正性肌力药物组合给药不会损害正性肌力作用正性肌力药物另外，HNO / NO 发挥其与肾上腺素能系统无关的正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也增加收缩力

8. 发明授权

US5789447A Nitric oxide releasing compounds as protective agents in ischemia reperfusion injury 失效
标题翻译：一氧化氮释放化合物作为缺血再灌注损伤中的保护剂
公开(公告)号：US5789447A
公开(公告)日：1998-08-04
申请号：US527314
申请日：1995-09-12
申请人： David A. Wink, Jr. , James B. Mitchell , Angelo Russo , Murali C. Krishna , Ingeborg Hanbauer , Matthew B. Grisham , Daniel Neil Granger
发明人： David A. Wink, Jr. , James B. Mitchell , Angelo Russo , Murali C. Krishna , Ingeborg Hanbauer , Matthew B. Grisham , Daniel Neil Granger
IPC分类号： C07D295/22 , A61K31/10 , A61K31/13 , A61K31/135 , A61K31/14 , A61K31/15 , A61K31/16 , A61K31/195 , A61K31/198 , A61K31/215 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/445 , A61K31/4468 , A61K31/495 , A61K31/496 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/04 , A61P3/08 , A61P7/00 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07D211/98 , C07D213/42 , C07D271/06 , A61K31/40
CPC分类号： A61K31/198 , A61K31/13 , A61K31/14 , A61K31/15
摘要： The present invention provides a method for treating oxygen free radical induced tissue damage associated with ischemia reperfusion injury, wherein nitric oxide is delivered to target cells/tissues through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen.
摘要翻译：本发明提供了一种治疗与缺血再灌注损伤相关的氧自由基诱导的组织损伤的方法，其中通过施用在生理条件下自发释放一氧化氮的一氧化氮的化合物将一氧化氮递送至靶细胞/组织，而不需要氧气的存在。

9. 发明授权

US5389675A Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents 失效
标题翻译：可用作心血管药物的一氧化氮 - 亲核试剂加合物的混合配体金属络合物
公开(公告)号：US5389675A
公开(公告)日：1995-02-14
申请号：US858885
申请日：1992-03-27
申请人： Danae D. Christodoulou , David A. Wink, Jr. , Larry K. Keefer
发明人： Danae D. Christodoulou , David A. Wink, Jr. , Larry K. Keefer
IPC分类号： C07F1/08 , A61K31/28 , A61K31/30 , A61K31/315 , A61K31/44 , A61P9/04 , A61P9/10 , A61P9/12 , C07F1/00 , C07F3/02 , C07F3/06 , C07F9/00 , C07F13/00 , C07F19/00
CPC分类号： C07F1/005 , A61K31/28 , A61K31/30 , A61K31/315 , A61K31/44 , C07F19/005 , C07F9/005 , Y10S514/906 , Y10S514/929
摘要： Mixed ligand metal complexes of nitric oxide-nucleophile adducts, useful as cardiovascular agents of the formula KA, wherein A is[(M).sub.x.sup.x' (L).sub.y (R.sup.1 R.sup.2 N-N.sub.2 O.sub.2).sub.x ], andK is a pharmaceutically acceptable counterion present in the composition when the overall charge of A is not zero, counterion K being present only in an amount to neutralize A. Methods of treating mammals with such compounds are provided. Pharmaceutical compositions containing such compounds are also provided.
摘要翻译：可用作式KA的心血管药物的一氧化氮 - 亲核试剂加合物的混合配体金属络合物，其中A为[（M）xx'（L）y（R1R2N-N2O2）x]，K为药学上可接受的抗衡离子当A的总电荷不为零时的组成，抗衡离子K仅存在于中和A的量。提供了用这些化合物治疗哺乳动物的方法。还提供含有这些化合物的药物组合物。

10. 发明授权

US5212204A Antihypertensive compositions and use thereof 失效
标题翻译：抗真菌组合物及其用途
公开(公告)号：US5212204A
公开(公告)日：1993-05-18
申请号：US423279
申请日：1989-10-18
申请人： Larry K. Keefer , David A. Wink , Tambra M. Dunams , Joseph A. Hrabie
发明人： Larry K. Keefer , David A. Wink , Tambra M. Dunams , Joseph A. Hrabie
IPC分类号： A61K31/13 , A61K31/135 , A61K31/185 , A61K31/19 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , C07C243/04 , C07C291/02
CPC分类号： C07C291/02 , Y10S514/929
摘要： This invention concerns antihypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein J is an organic or inorganic moiety, M.sup.+x is a pharmaceutically acceptable cation and the compound decomposes under physiological conditions to release nitric oxide (NO).
摘要翻译：本发明涉及抗高血压组合物和降低哺乳动物血压的方法。组合物的活性组分是下式的化合物：其中J是有机或无机部分，M + x是药学上可接受的阳离子，并且该化合物在生理条件下分解以释放一氧化氮（NO）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式